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Abstract 
Objective: High therapy dropout rates among adolescents have been reported, but little is 
known about whether dropout is associated with poor outcomes. This study aimed to examine 
clinical outcomes in adolescents with depression who dropped out of psychological therapy 
and to determine if this varied by treatment type. 
Method: Data was drawn from the IMPACT study; a randomised controlled trial, comparing 
a Brief Psychosocial Intervention, Cognitive-Behavioral Therapy and Short-Term 
Psychoanalytic Psychotherapy in the treatment of adolescent major depression. The sample 
comprised 406 adolescents with a diagnosis of major depression, 169 of whom dropped out 
of treatment prior to the planned end of therapy. Primary outcome was self-report Mood and 
Feelings Questionnaire (MFQ); secondary outcomes were Health of the Nation Outcome 
Scale for Children and Adolescents, Revised Children’s Manifest Anxiety Scale, Modified 
Leyton Obsessional Inventory and Clinical Diagnosis. 
Results: During follow-up there was a non-significant trend for dropouts to report higher 
depressive symptoms than completers. However, modeling showed insufficient evidence for 
an association between dropout and outcomes. 
Conclusion: In contrast to studies of adult therapy, there was no strong evidence that 
adolescent patients who dropped out had poorer clinical outcomes compared with those who 
completed therapy, when dropout was defined as ending treatment without agreement of the 
therapist. This challenges us to understand why adolescents stop going to therapy, how 
dropout should be defined, and whether what is prescribed is what is always needed.  
Clinical trial registration information: Improving Mood and Preventing Relapse With 
Psychoanalytic Psychotherapy and Cognitive Behaviour Therapy; http://www.isrctn.com/; 
83033550.  
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Introduction 
Depression has an estimated 12-month prevalence rate of 7.5% in adolescence,1 making it 
one of the most common psychiatric disorders in adolescence2 and a significant public health 
concern. There is now firm evidence that around 70% adolescents with depression who 
engage in therapy will improve up to a year after treatment.3 There remains considerable 
concern however about treatment resistance including adolescents who drop out of therapy, 
with dropout rates estimated between 28% and 75%.4  
 Dropout has been conceptualised as a client ending therapy prematurely, where they 
have made the decision unilaterally without agreement of their therapist.5 The most well 
accepted definition of dropout is based on therapist judgement that the client ended treatment 
without their agreement, although other definitions include a client ending treatment prior to 
completing a pre-specified number of sessions or if they fail to attend their last scheduled 
appointment.6 Kazdin’s risk-factor model outlines conditions that may increase the likelihood 
of dropout, such as socio-economic disadvantage and greater symptom severity.7 This model 
has been empirically supported, at least in the treatment of conduct disorders, suggesting that 
it is the most troubled and disadvantaged youth who are at greatest risk of dropout.4 
Researchers have also found that greater barriers experienced when attending treatment, such 
as practical issues or not perceiving the treatment as relevant, increase the likelihood of 
dropout.8 It is unclear whether these findings hold true for other diagnostic groups. Our 
previous study, drawing on the same dataset as the present study, tested the risk-factor model 
in adolescents receiving treatment for depression and found that increased age and antisocial 
behaviour were significant predictors of dropout. However, prediction of dropout from pre-
treatment characteristics was overall poor, and various factors were not predictive of dropout, 
including sex, ethnic minority status, parental wellbeing and symptom severity (including 
depression, anxiety, obsessionality, self-harm, risk taking and comorbidity). Thus, there was 
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little evidence that it was the most impaired adolescents receiving treatment for depression 
who dropped out.9   
 As talking therapies have been found to be effective, it seems reasonable to expect 
that dropping out of treatment would be associated with poorer outcomes.10 Adults who 
complete therapy for depression have consistently been found to improve more than clients 
who drop out.11–13 However, we cannot assume that findings from studies with adult clients 
can be generalised to adolescents. Help seeking in youth often does not come from the child 
or adolescent themselves, but instead, is frequently initiated by an adult, such as their parent 
or caregiver.7 Adolescents may be less motivated to engage in therapy than adults if they 
haven’t sought therapy for themselves, so it cannot be assumed that the implications of 
dropout will be comparable for adolescents and adults.  
Several studies found children with conduct problems (and/or their parents) who drop 
out have poorer clinical outcomes by the end of treatment, compared with those who 
complete treatment.14–18 One study investigated longer-term outcomes associated with 
dropout, and found that poorer outcomes were maintained approximately 20-months after 
treatment began.16 However, two of these studies reported that dropouts were more impaired 
at baseline, suggesting that difference in outcomes may in part be due to pre-treatment 
factors.14,15 Two studies included samples of both children and adolescents (aged below 17-
years) and found that those who completed treatment made greater gains than those who did 
not.19,20 It cannot be assumed that findings from youth with conduct disorders generalize to 
those seeking treatment for depression. The phenomenology of these clinical populations 
differs substantially and thus the reasons for dropout may differ between them. Depression in 
youth is characterised by hopelessness and social withdrawal,21 which may contribute to their 
decisions to drop out through feeling hopeless that it won’t help. In contrast, conduct 
problems are characterised by antisocial and defiant behaviours22 and so dropping out may be 
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a sign of acting out against the therapist or service. There may well be different influences, 
causes or reasons for dropout between these diagnostic groups. The models of treatment also 
differ, with treatment for child conduct problems placing more emphasis on parent training 
and parental involvement in treatment compared with interventions for adolescent 
depression.22,23 The inherent differences in the phenomenology and treatment of these 
disorders means previous findings of outcomes in young people with conduct problems may 
not transfer to those with depression. Many of these studies have been conducted with 
younger children, yet adolescents have distinct developmental tasks,24,25 and thus there is a 
strong argument for studying the implications of dropout for adolescents with depression in 
their own right.  
 Currently there is a dearth of knowledge about adolescents with depression who drop 
out of therapy. We addressed this gap in the literature within the context of a randomised 
controlled trial (RCT) evaluating the effectiveness of psychological therapies for adolescent 
depression.3 This study aimed to examine the association between dropout and clinical 
outcomes among adolescents who received therapy for depression. In keeping with the aim of 
the RCT, we focused on long-term outcomes.  
 
Method 
Design 
We conducted secondary analysis of the IMPACT multisite RCT comparing three 
psychological interventions in the treatment of moderate/severe depression in adolescents 
(ISRCTN register reference: ISRCTN83033550).3,26. Adolescents were referred from Child 
and Adolescent Mental Health Services across three regions in England. Inclusion criteria 
were a DSM-IV diagnosis of unipolar major depressive disorder,27 measured by the Kiddie-
Schedule for Affective Disorders and Schizophrenia (Kiddie-SADS),28 and aged 11-17 years 
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at referral. Exclusion criteria were generalised learning difficulties, pervasive developmental 
disorder, eating disorder, bipolar disorder, schizophrenia, and pregnancy. Eligible patients 
were randomly allocated to one of three manualised treatments: 
a) Brief Psychosocial Intervention (BPI). Up to 12 sessions, focused on engagement, 
psychoeducation about depression, problem solving, and supporting activation 
through engaging in interpersonal activities and physical wellbeing.  
b) Cognitive-Behavioral Therapy (CBT). Up to 20 sessions, based on formulation of the 
adolescents’ current problems, precipitating and maintaining factors, focusing on 
explicit, tangible and shared goals. 
c) Short-Term Psychoanalytic Psychotherapy (STPP). 28 weekly sessions with the 
adolescent, based on close and detailed observation of the relationship the adolescent 
makes with their therapist, with a focus on better self-understanding of feelings and 
difficulties in their life.  
The treatment manuals are available at: http://dev.psychiatry.cam.uk/projects  
Outcome assessments took place after randomisation, at 6 and 12-weeks (during 
treatment), 36-weeks (completed treatment for >95%), and 52 and 86-weeks (long-term follow-
ups).  
 All three therapies were equivalent in clinical and cost-effectiveness, with 78% of 
adolescents showing clinically meaningful reductions in their symptoms of depression and 
improved functioning approximately one-year after the end of treatment.3 37% of adolescents 
dropped out of their allocated therapy, and 10% did not take up the therapy on offer.9 The 
hypothesis tested in this study was that one-year after the end of treatment for depression 
adolescents who dropped out of their offered therapy would have poorer outcomes than 
adolescents who completed therapy.  
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Ethical considerations 
The IMPACT study protocol was approved by the Cambridgeshire 2 Research Ethics 
Committee (reference:09/H0308/137). Fully informed written consent was obtained from 
participants, or parents for those under the age of 16.  
  
Measures 
The primary outcome was self-report depression symptoms, measured by the Mood and 
Feelings Questionnaire (MFQ).29 Secondary outcomes were Health of the Nation Outcome 
Scale for Children and Adolescents (HoNOSCA); a measure of psychosocial impairment,30 
self-report scores on the Revised Children’s Manifest Anxiety Scale (RCMAS)31 and revised 
Leyton Obsessional Inventory (LOI).32 Presence of current major depressive disorder was 
assessed by the Kiddie-SADS28 at post treatment follow-ups (36, 52 and 86-weeks). 
 
Operationalising therapy completion and dropout 
Participants were retrospectively classified as dropouts if they took up the therapy on offer 
but ended it without the mutual agreement of their therapist, as determined by the therapist's 
'end of treatment’ form, regardless of how many sessions they attended. This definition was 
selected as is the most well accepted in the contemporary dropout literature,9 and allows for 
the reality that dropout can happen after any number of sessions. To address the limitation 
that this definition includes adolescents that attended a significant proportion of planned 
sessions and those who dropped out at an early stage, sensitivity analyses were conducted to 
consider different approaches to defining dropout, based on when dropout occurred. In the 
sensitivity analyses, dropout was defined as when the ending of treatment was not agreed 
with the therapist, and a) it was prior to the adolescent completing 25% of their planned 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
8
sessions, b) prior to the adolescent completing 50% of their planned sessions and c) prior to 
the adolescent completing 75% of their planned sessions.  
 Participants were classified as treatment completers if their therapist recorded that 
treatment had ended as planned or by mutual agreement.  
 Participants were classified as non-starters if they did not attend any therapy sessions. 
Non-starters do not take up the treatment on offer, which is considered as representing a 
distinct phenomenon from that of dropout.33 
 
Statistical analysis 
Data analyses were conducted in R V3.3.2.34 Multilevel modelling was used to examine 
whether dropouts and completers differed in their rate of change between treatment arms. 
Treatment arms, therapy ending and time were tested as predictors of outcomes for the 
continuous outcome variables (MFQ; HoNOSCA; RCMAS; LOI). Therapy ending was a 
dichotomous variable (0=completed; 1=dropped out). The models had a three-level structure, 
with repeated measures nested within participants, who in turn were nested within therapists. 
For 22 participants the therapist was unknown; these were treated as their therapists’ only 
case. Participant random slopes for the Time variable were included in all models, to allow 
for variation in the rate of change between participants. In addition, age and antisocial 
behaviour (measured using the Antisocial Behaviour Questionnaire)3 were controlled for as 
they were known to differ between completers and dropouts.9  
 The relationship between time and outcome was not expected to be linear. To account 
for greater rate of change early in treatment, time was log-transformed, using the equation 
log(Time+1). This enabled the non-linear relationship between time and outcomes (MFQ, 
HoNOSCA, RCMAS and LOI) to be modeled using linear regression. Square-root 
transformation of time yielded a better fit for modeling outcomes on the RCMAS according 
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to Akaike’s Information Criterion (AIC; Akaike, 1973) and Bayesian Information Criterion 
(BIC; Schwarz, 1978). Square-root transformation of time was therefore used for modeling 
outcomes on the RCMAS. The best fitting model was selected using likelihood ratio tests, the 
AIC and BIC, with a smaller AIC and BIC representing a better fitting model.  
 To investigate whether risk of meeting diagnostic criteria for depression at 36, 52 and 
86-weeks differed between completers and dropouts, in each treatment arm, mixed effect 
logistic regression analyses were used. All participants met diagnostic criteria for depression 
at baseline, so logistic regression analyses were used to test dropout as a predictor of 
depression at the long-term follow-up assessments. Mixed effect models were used to 
account for therapist effects. The dependent variable was depression diagnosis (measured by 
the Kiddie-SADS), and predictor variables were interaction terms for Treatment Arm X 
Therapy Ending. Models were run with completers in each treatment arm coded as the 
reference group, to estimate the association between dropout and outcomes in each treatment 
arm. Age and antisocial behavior were included as covariates.  
 Sensitivity analyses were conducted to test whether the conclusions were sensitive to 
how dropout was defined.  
 
Results 
Participants  
The IMPACT sample consisted of 465 participants, as previously reported.3 Cases were 
excluded if it was unknown how therapy ended, due to incomplete therapist records (n = 12), 
or if they did not start treatment (n = 47), providing a sample of 406 participants for the 
present study.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
10
 Participants ranged from 11 to 17-years (M=15.56, SD=1.44) at baseline. 303 (75%) 
were female participants and 103 (25%) were male participants. Ethnicity was 81% white, 
7% mixed ethnic background, 2% Asian, 3% black, 3% other and 4% ethnicity unknown.  
 
Dropout rates, treatment duration and session attendance 
Of the 406 participants, 237 completed therapy and 169 dropped out. Dropout by treatment 
arm, number of sessions attended and treatment durations are shown in Table S1 (available 
online). On average, participants in all three arms attended far fewer sessions than the 
manuals prescribed. The majority of dropouts in all treatment arms attended less than 50% of 
the prescribed sessions, whereas completers tended to attend more than 50% of intended 
sessions. Treatment duration from the first to last session was substantially lower for 
dropouts compared with completers, indicating that dropout tended to occur early in therapy.  
 
Clinical outcomes associated with dropout 
Descriptive statistics on each outcome measure for dropouts and completers in the three 
treatment arms, at each timepoint, show little difference in baseline scores between 
completers and dropouts (Table 1). In CBT and STPP, dropouts tended to have slightly 
poorer outcomes than completers; in BPI, outcome differences between dropouts and 
completers were smaller and sometimes in the opposite direction, with dropouts sometimes 
having better outcomes. 
[Table 1] 
To model outcomes on the MFQ, Model 1 predicted the trajectory of change in MFQ scores 
with Time (Log(Time+1)), Treatment Arms and Therapy Ending as the independent 
variables, with random intercepts for therapists and participants, and participant random 
slopes for the effect of time, controlling for age and antisocial behaviour. This assumed the 
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rate of change was the same for all groups. In Model 2, two-way interaction terms (Time X 
Treatment Arms; Time X Therapy Ending) were added to the model, which tested whether 
change was dependent on therapy ending and treatment arm, without an interaction between 
therapy ending and treatment arm. This did not improve the model fit, according to the AIC, 
BIC and a likelihood ratio test (LRT(3)=2.82, p=0.42). In Model 3, three-way interaction 
terms (Time X Treatment Arms X Therapy Ending) were added to the model, to test whether 
the association between dropout and outcomes differed between the treatment arms. This did 
not improve the model fit, based on the AIC, BIC and a likelihood ratio test (LRT(4)=6.01, 
p=0.20). Therefore we found no strong evidence for an association of dropout with MFQ 
across all three treatments, nor for an association of dropout with MFQ for any treatment arm 
(for model estimates, see Table S2; available online). Model 3 is plotted in Figure 1.  
[Figure 1] 
Outcomes on the HoNOSCA, RCMAS and LOI were modeled using the same strategy 
described above. Adding two-way interaction terms and three-way interaction terms did not 
improve the fit of the models, for any of the outcome measures (for model estimates, see 
Tables S3-S5; available online). Thus, no strong evidence was found for an association 
between dropout and outcomes on any of the outcome measures. 
Finally, mixed effect logistic regression analyses were used, testing the main effects 
of each treatment arm and interaction terms for Treatment Arm X Dropout as predictors of 
depression diagnosis at 36, 52 and 86-weeks (Table 2). At 36-weeks, those who dropped out 
of BPI were estimated to be 71% less likely to meet diagnostic criteria for depression 
compared with those who completed BPI (OR=0.29, CI 0.10:0.82), showing evidence 
contrary to our hypothesis. This association was not maintained in the longer term, as the BPI 
X Dropout terms were not significant at 52 and 86-weeks. In CBT and STPP, some evidence 
was found for an association between dropout and outcomes in the expected direction. At 36-
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
12
weeks, those who dropped out of STPP were estimated to be 2.7 times more likely to meet 
diagnostic criteria for depression compared with those who completed STPP (OR=2.67, CI 
1.11:6.41). A longer-term association of dropout and depression diagnosis was not found in 
STPP, as the STPP X Dropout terms were not significant at 52 and 86-weeks. In CBT, there 
was not a significant effect of dropout at 36-weeks on the odds of meeting diagnostic criteria 
for depression. However, at 52-weeks, dropping out of CBT was estimated to increase the 
odds of meeting diagnostic criteria for depression six-fold (OR=6.09, CI 2.05:18.10). This 
difference was statistically significant, yet the confidence intervals were rather wide, 
indicating that this association could not be estimated with a great deal of precision, and 
should be viewed with caution. This association between dropout and depression diagnosis 
was not maintained in the longer-term, at 86-week follow-up (Table 2). 
[Table 2] 
 
Exploratory Analysis 
The trial was not designed to have sufficient power for these secondary analyses. We 
considered that the findings presented may be due to inadequate power to detect an 
association between dropout and outcomes, overall or separately for the three treatments. We 
decided to present coefficient estimates from Model 2 and Model 3, as an exploratory 
analysis.  
 Table 3 shows estimated difference in MFQ scores between dropouts and completers 
in each treatment arm. The estimates of the association between dropout and outcome (not 
accounting for treatment arm) were derived from Model 2, and estimates for each treatment 
arm were derived from Model 3. In BPI and STPP, dropout estimates showed little indication 
of an association of dropout with MFQ scores at 36, 52 and 86-weeks, as the 95% confidence 
intervals contained zero. In CBT however, the confidence intervals did not contain zero and 
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contained the value of five (considered to be an important difference on the MFQ3). This 
shows some weak evidence for an association of dropout with MFQ scores in CBT, but 
should be viewed cautiously due to the exploratory nature of these analyses. On the RCMAS, 
the same pattern was observed: the 95% confidence intervals for dropout estimates contained 
zero for the BPI and STPP arms at all time-points, but not for CBT. This provides some 
indication of a possible association of dropout on outcomes on the RCMAS in the CBT arm, 
at 36, 52 and 86-weeks. On the HoNOSCA and LOI, the 95% confidence intervals for 
dropout estimates at all timepoints and all three treatment arms contained zero, providing no 
evidence for an association of dropout and outcomes on these measures.  
 Table 3 also shows estimated differences in outcome scores between dropouts and 
completers in each treatment arm at the 6 and 12-week assessments, to explore whether 
progress (or lack of) during treatment was associated with dropout. The confidence intervals 
all contain zero, thus there is no strong evidence for a difference between dropouts and 
completers in the rate of change in the early part of treatment.   
[Table 3] 
Sensitivity analyses were conducted to test whether the conclusions were sensitive to how 
dropout was defined. The results were found to be robust, as they did not change when 
dropouts were re-classified as completers if they attended more than 25%, 50% and 75% of 
the planned sessions. No evidence was found for therapist effects in any of the models.  
 
Discussion  
The IMPACT trial investigated psychological therapies in the treatment of adolescent 
depression, and found no statistically significant difference in clinical outcomes between 
three treatment arms.3 The present study investigated whether dropout was associated with 
outcomes by conducting secondary analysis of the IMPACT dataset. It was hypothesised that 
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adolescents who dropped out of therapy would have poorer long-term outcomes compared 
with those who completed therapy, in the three treatments.  
 Modeling showed insufficient evidence to conclude an association between dropout 
and outcomes, for four of the five outcome measures investigated, based on the planned 
analyses. The only outcome measure where there was statistically significant evidence that 
dropout may be associated with poorer outcomes was depression diagnosis, in CBT and 
STPP. CBT dropouts were estimated to be six times more likely to meet diagnostic criteria 
for depression at 52-weeks compared with completers, yet this could not be estimated with a 
great deal of precision, and any association was not maintained at 86-weeks. STPP dropouts 
were estimated to be 2.7 times more likely to meet diagnostic criteria for depression at 36-
weeks than completers, but this difference was not maintained at the longer-term follow-ups. 
Counter to our hypothesis, BPI dropouts were estimated to be 71% less likely to meet 
diagnostic criteria at 36-weeks than completers. No such difference in depression diagnosis 
between BPI dropouts and completers was observed at the later follow-ups. Thus, there was 
some evidence for an association between dropout and outcomes in CBT and STPP after the 
end of treatment, yet at 86-weeks, there were no significant differences between dropouts and 
completers in any treatment arm.  
 As these were secondary analyses of the IMPACT dataset, we were mindful this study 
was likely to be underpowered. To provide an indication of power, we explored the estimated 
difference in outcomes between dropouts and completers with confidence intervals in each 
treatment arm. Based on dropout estimates, some evidence for an association of dropout with 
outcome was found in the CBT arm, weaker evidence in the STPP arm, and little evidence in 
the BPI arm. This evidence must be considered weak because the association between 
dropout and outcomes were estimated from models that were rejected due to insignificant 
results. The wide confidence intervals of dropout estimates show we were unable to estimate 
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differences in outcomes associated with dropout with good precision, due to the sample size. 
However, these estimates may be useful for future researchers conducting systematic reviews 
or meta-analyses, to obtain better estimates of the association of therapy dropout with 
outcomes in adolescents. 
 Given that the interventions were designed to improve depressive pathology and 
wellbeing, it was surprising to find limited evidence of an association between dropout and 
adolescents’ long-term outcomes. This raises important questions about how dropout is 
defined and why adolescents drop out of therapy. Previous research cited not perceiving need 
for further treatment as a common reason clients give for stopping therapy.24,37 It is possible 
that some young people dropped out because they did not feel in need of further treatment or 
because they perceived it was not helping. However, our exploratory analyses found no 
strong evidence for a difference between dropouts and completers in the rate of symptom 
change in the 6 and 12-week assessments. Future research should include adolescents’ 
perspectives as to the reasons they dropped out of therapy.  
 Interestingly, and in contrast to the results presented here, research with child and 
adult patients has found dropout to be associated with poorer clinical outcomes.11,13–20 This 
age effect may reflect a developmental difference in the meaning of depressive symptoms 
and/or syndrome. Adolescents have distinctive developmental tasks, including formation of 
identity, becoming more autonomous and questioning adult authority.24,25 Perhaps therapists 
need to be sensitive to and assess the nature of adolescent maturation and how this may 
impact on the planned treatment. For example, if becoming independent from adults becomes 
apparent during treatment, this may enable the decision to stop therapy and be more 
autonomous in subsequent recovery.24 This would support the notion that dropping out of 
therapy may not always be a bad thing for adolescents. Further research is required to test this 
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developmentally sensitive speculation including for treatments of adolescents presenting with 
other disorders. 
 It is important to acknowledge the episodic nature of depression, as the likelihood of 
recurrence and relapse within one year, even in successfully treated depression, is estimated 
between 50-75%.38 Improvements observed may in part reflect the natural course of the 
disorder, and some adolescents may recover regardless of whether they complete treatment or 
not. We also note there were relatively few pre-treatment differences between completers and 
dropouts, as dropouts were not found to have greater symptom severity than completers at 
baseline.9 However, at baseline, age and antisocial behavior were higher for dropouts than 
completers. These variables were included as control variables,9 and may moderate the 
relation between dropout and outcome.  
 This was the first known study to investigate clinical outcomes associated with 
dropout in adolescents receiving therapy for depression. While absence of strong evidence is 
not evidence of absence of an effect, these findings challenge common assumptions that 
dropout equates to poor clinical outcomes. Research is needed to further investigate the 
implications of dropout.  
 This study had several limitations. It was not designed (or powered) to formally test 
or confirm these secondary hypotheses. These findings must be viewed with caution and 
further research is required to test the association between dropout and clinical outcomes. 
The 86-week follow-up may be too short for some dropout manifestations to be measured. 
This study was also limited by our models not taking into account the point at which dropout 
occurred, as we did not have a measure of outcome at the point of dropout.   
 Dropout was defined as the adolescent ending therapy without the therapist’s 
agreement. The limitation of this definition is that it is highly dependent on the therapists’ 
views about the appropriateness of ending treatment. Moreover, it does not account for when 
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dropout occurred. To overcome this issue, sensitivity analyses were conducted to consider 
whether the findings differed as a function of the definition, which they did not. It was 
surprising that little evidence for an association of dropout and outcomes was found, given 
that dropout was based on therapists’ judgement as to whether they agreed with the ending. 
This calls into question issues regarding operational definitions of dropout, and more broadly, 
about the nature of dropout itself. It must be acknowledged that it is unknown how 
representative this sample was of the population, as it was based on recruitment from 
specialist adolescent mental health services and was not designed to be representative of 
these forms of major depression in the community. This means we can only comment on 
drop out from therapy of those young people with depression in the community who are able 
to access treatment. In addition, as these findings were in the context of an RCT, it is 
unknown how generalizable they are to routine clinical practice, but provide an important 
starting point in the study of dropout and outcome.  
 We note that the dropout rate in this sample (37%) was substantially higher than the 
rate of consent withdrawal (10.9%) reported in the TADS trial for adolescent depression.39 
This may be due to the short treatment duration in TADS compared with the IMPACT trial. 
However, these groups are not directly comparable, as TADS only reported the consent 
withdrawal rate, whereas dropout was operationally defined in this study based on the ending 
of treatment not being agreed with the therapist. This means some adolescents were classified 
as having dropped out as they stopped attending their sessions or were discharged due to non-
attendance, without necessarily having formally withdrawn consent for treatment. This is 
likely to have contributed to the marked difference in dropout rates in our study compared 
with TADS. This reflects issues with inconsistency in how dropout is operationally defined in 
the literature. There is a need for standardized reporting of treatment dropout in clinical 
trials,40 to facilitate dropout comparisons across studies.   
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 In conclusion, dropout is a common phenomenon in adolescents receiving therapy for 
depression.9 Given that psychotherapy is generally associated with positive clinical 
outcomes, it is usually assumed that dropping out of psychotherapy is an undesirable way for 
it to conclude. Most studies of dropout and outcome with children and adults have supported 
this assumption.11,13–20 However, little evidence for an association of dropout and clinical 
outcomes was found in this study, particularly by the final follow-up at 86-weeks, suggesting 
that dropping out of treatment for many adolescents with depression may not be a signature 
of poor long-term outcome, when defined as ending treatment without agreement from the 
therapist. These findings should be viewed as exploratory and a sufficiently powered study to 
test the prognostic implications of treatment dropout is required. 
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Table 1: Outcomes at Each Timepoint, for Dropouts and Completers in Each Treatment Arm 
Outcome  Timepoint BPI CBT STPP 
Dropouts Completers Dropouts Completers Dropouts Completers 
MFQ Baseline (N=406) 46.53 46.28 45.49 46.18 44.77 44.66 
6-weeks (n=285) 39.02 36.26 38.43 33.40 34.05 37.35 
12-weeks (n=301) 35.76 34.66 38.06 29.27 32.82 34.60 
36-weeks (n=289) 26.66 32.20 27.50 23.40 30.89 23.80 
52-weeks (n=297) 25.96 24.94 30.57 22.61 25.80 21.33 
86-weeks (n=319) 22.53 24.32 26.31 19.60 24.68 18.27 
 HoNOSCA Baseline (n=380) 19.89 18.48 19.00 17.62 18.09 18.38 
6-weeks (n=252) 15.50 14.51 15.28 13.47 14.13 15.01 
12-weeks (n=271) 17.46 13.16 14.28 11.10 12.11 13.36 
36-weeks (n=241) 11.94 11.69 9.81 9.70 12.26 8.99 
52-weeks (n=235) 8.78 9.95 12.09 7.62 10.41 7.15 
86-weeks (n=250) 7.72 8.48 9.01 6.36 8.35 7.54 
Modified LOI Baseline (n=402) 11.07 9.45 10.15 11.08 9.40 8.68 
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6-weeks (n=282) 9.32 7.32 8.50 6.79 7.43 7.97 
12-weeks (n=298) 7.97 6.37 7.83 6.21 7.13 7.52 
36-weeks (n=283) 6.54 6.02 5.50 4.28 5.90 4.65 
52-weeks (n=281) 7.19 5.00 5.28 4.83 5.07 4.61 
86-weeks (n=298) 5.79 4.75 5.39 4.54 4.20 3.46 
 RCMAS Baseline (n=405) 42.37 40.42 40.72 41.71 40.44 40.10 
6-weeks (n=283) 36.39 36.20 39.34 35.90 35.58 38.70 
12-weeks (n=299) 35.24 35.09 38.95 32.91 34.02 34.79 
36-weeks (n=285) 29.46 33.23 29.54 25.96 29.67 27.89 
52-weeks (n=285) 26.27 27.75 31.21 24.39 27.19 24.19 
86-weeks (n=301) 24.00 25.57 28.41 22.59 24.52 22.60 
% meeting criteria 
for depression  
6-weeks (n=268) 78% 67% 74% 52% 64% 61% 
12-weeks (n=282) 52% 56% 65% 41% 57% 56% 
36-weeks (n=263) 22% 52% 36% 28% 49% 26% 
52-weeks (n=247) 32% 29% 54% 17% 31% 22% 
86-weeks (n=262) 15% 31% 37% 18% 19% 9% 
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Note: BPI =Brief Psychosocial Intervention; CBT = Cognitive-Behavioral  Therapy; HoNOSCA = Health of the Nation Outcomes Scales Child 
and Adolescent; LOI = Leyton Obsessional Inventory; MFQ = Mood and Feelings Questionnaire; RCMAS = Revised Children’s Manifest 
Anxiety Scale; STPP = Short Term Psychoanalytic Psychotherapy. 
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Table 2. Mixed Effects Logistic Regression Analyses Predicting Depression Diagnosis at 36, 52 and 86-weeks 
 Variable 36-weeks (n=260) 
OR (95% CI) 
52-weeks (n=245) 
OR (95% CI) 
86-weeks (n=237) 
OR (95% CI) 
Fixed effects Constant 2.31 (0.11:49.36) 0.11 (0.00:3.43) 0.05 (0.00:2.31) 
Age 0.96 (0.79:1.17) 1.10 (0.89:1.36) 1.16 (0.91:1.47) 
 
Anti-social behaviour 0.96 (0.88:1.05) 0.94 (0.84:1.04) 0.98 (0.87:1.11) 
 
Dropout 0.29* (0.10:0.82) 1.29 (0.44:3.81) 0.44 (0.13:1.49) 
 
CBT 0.39* (0.18:0.83) 0.51 (0.21:1.22) 0.54 (0.22:1.30) 
 
CBT X Dropout 5.01* (1.15:21.84) 4.72* (1.02:21.84) 6.01* (1.19:30.43) 
 
STPP 0.34*** (0.16:0.76) 0.74 (0.30:1.81) 0.24* (0.07:0.76) 
 
STPP X Dropout  9.26*** (2.38:36.04) 1.10 (0.25:4.82) 5.39 (0.89:32.72) 
Random effects Therapist variance (SD) 0.00  0.00 0.00  
ORs for Treatment Arm X Dropout interaction terms 
Reference group:     
BPI Completers BPI X Dropout 0.29* (0.10:0.82) 1.29 (0.44:3.81) 0.44 (0.13:1.49) 
CBT Completers CBT X Dropout 1.44 (0.51:4.09) 6.09*** (2.05:18.10) 2.63 (0.93:7.50) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
STPP Completers STPP X Dropout 2.67* (1.11:6.41) 1.42 (0.52:3.90) 2.36 (0.62:8.96) 
Note: Mixed effects logistic regression models predicted depression diagnosis (measured by the Kiddie-SADS [Kiddie Schedule for Affective 
Disorders and Schizophrenia]), with therapist effects and controlling for age and antisocial behaviour. Sample based on the number of 
participants who completed the Kiddie-SADS at that timepoint. BPI = Brief Psychosocial Intervention; CBT = Cognitive-Behavioral  Therapy; 
OR = odds ratio. STPP = Short Term Psychoanalytic Psychotherapy. 
 *p < .05, ***p < .001 
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Table 3: Mean Estimated Difference in Outcomes Associated With Dropout With Confidence Intervals, in Each Treatment Arm 
Measure Timepoint Overall dropout 
effecta (95% CI)  
BPI dropout 
effectb (95% CI) 
CBT dropout 
effectb (95% CI) 
STPP dropout 
effectb (95% CI) 
MFQ 6-weeks 0.47 (-1.56:2.49) -1.22 (-4.73:2.29) 2.78 (-0.76:6.32) -0.19 (-3.60:3.21) 
12-weeks 0.92 (-1.21:3.04) -1.53(-5.23:2.17) 3.70 (-0.00:7.40) 0.52 (-3.03:4.08) 
36-weeks 1.81 (-0.86:4.49) -2.13 (-6.82:2.56) 5.51 (0.86:10.16) 1.93 (-2.52:6.39) 
52-weeks 2.13 (-0.82:5.08) -2.35 (-7.52:2.83) 6.16 (1.03:11.28) 2.44 (-2.47:7.35) 
86-weeks 2.60 (-0.80:6.00) -2.67 (-8.65:3.30) 7.12 (1.21:13.03) 3.19 (-2.47:8.85) 
 HoNOSCA 6-weeks 0.69 (-0.37:1.74) 0.75 (-1.07:2.56) 1.39 (-0.46:3.23) -0.11 (-1.90:1.68) 
12-weeks 0.72 (-0.31:1.76) 0.44 (-1.36:2.23) 1.43 (-0.39:3.24) 0.26 (-1.48:2.00) 
36-weeks 0.79 (-0.41:2.00) -0.17 (-2.28:1.93) 1.51 (-0.61:3.63) 0.98 (-1.02:2.97) 
52-weeks 0.82 (-0.49:2.13) -0.39 (-2.69:1.91) 1.54 (-0.79:3.86) 1.24 (-0.94:3.41) 
86-weeks 0.86 (-0.66:2.37) -0.72 (-3.36:1.93) 1.58 (-1.10:4.26) 1.62 (-0.88:4.12) 
LOI – adolescent 
version  
6-weeks 0.58 (-0.34:1.49) 1.18 (-0.41:2.76) 0.12 (-1.49:1.72) 0.41 (-1.15:1.97) 
12-weeks 0.64 (-0.25:1.54) 1.09 (-0.47:2.65) 0.37 (-1.19:1.93) 0.45 (-1.07:1.97) 
36-weeks 0.78 (-0.17:1.72) 0.93 (-0.74:2.60) 0.87 (-0.77:2.52) 0.52 (-1.07:2.11) 
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52-weeks 0.83 (-0.16:1.82) 0.87 (-0.88:2.63) 1.05 (-0.67:2.77) 0.55 (-1.12:2.21) 
86-weeks 0.90 (-0.18:1.98) 0.79 (-1.14:2.71) 1.32 (-0.56:3.19) 0.59 (-1.22:2.39) 
RCMAS 6-weeks 0.23 (-1.26:1.73) 0.51 (-3.12:2.10) 1.61 (-1.00:4.23) -0.44 (-2.94:2.07) 
12-weeks 0.48 (-1.19:2.15) -0.98 (-3.91:1.96) 2.55 (-0.36:5.46) -0.19 (-2.97:2.60) 
36-weeks 0.97 (-1.33:3.27) -1.89 (-5.95:2.18) 4.40 (0.42:8.39)  0.30 (-3.52:4.12) 
52-weeks 1.14 (-1.43:3.72) -2.21 (-6.77:2.34) 5.07 (0.60:9.53)  0.48 (-3.80:4.75) 
86-weeks 1.40 (-1.61:4.41) -2.70 (-8.03:2.62) 6.05 (0.83:11.27) 0.74 (-4.26:5.73) 
Note: Mixed model estimates of mean differences for dropouts compared with completers at 6, 12, 36, 52 and 86-weeks. Analysis used therapist, 
participant and slope random effects, and tested three-way interactions Time(log-transformed) X Treatment arm X Dropout, controlling for age 
and antisocial behaviour. BPI = Brief Psychosocial Intervention; CBT = Cognitive-Behavioral  Therapy; HoNOSCA = Health of the Nation 
Outcome Scale for Children and Adolescents; LOI = Leyton Obsessional Inventory; MFQ = Mood and Feelings Questionnaire; RCMAS = 
Revised Children’s Manifest Anxiety Scale; STPP = Short Term Psychoanalytic Psychotherapy. 
aDerived from Model 2 (which tested two-way interactions: Time X Treatment Arms; Time X Therapy Ending);  
bDerived from Model 3 (which tested three-way interactions: Time X Treatment Arms X Therapy Ending). 
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Figure 1. Estimated Change in Mood and Feelings Questionnaire (MFQ) Scores Over 
Time for Completers and Dropouts in Each Treatment Arm 
Note: BPI = Brief Psychosocial Intervention; CBT = Cognitive-Behavioral Therapy; STPP = 
Short Term Psychoanalytic Psychotherapy. 
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